People in the study are placed into one of two groups. One group has the blood flow checked with indocyanine green fluorescence imaging, which means the dye is used so the surgeon can see how blood moves through the flap. The other group is checked with standard clinical assessment, which means the usual way of judging the flap during surgery. After the operation, the flap is followed for a short time to see how it heals and whether any further treatment is needed.

Participants will be assigned to receive one of the two treatments through the mouth. The study involves monitoring the intensity of mouth pain during and after the use of these medications. This process will take place during radiotherapy, which is a common treatment for cancer that uses radiation to target cells, and for several weeks following the completion of that treatment.

The study uses a medication called zanidatamab (also known as JZP598), which is given through an intravenous infusion. This medicine is a powder that is first made into a concentrated solution before being given to patients. The maximum daily dose that can be given is 2400 milligrams, and treatment may continue for up to three years.

The main goal of this research is to determine how well zanidatamab works in treating these different types of cancer. The study will look at whether tumors respond to the treatment by shrinking or disappearing. Doctors will monitor patients regularly using scans to check how the tumors are responding to the treatment and to watch for any side effects that may occur.

The purpose of the study is to evaluate the effectiveness of ezabenlimab, an experimental medication given as an intravenous infusion, which means it is delivered directly into a vein. Participants in the study will receive this treatment to see if it can help prevent the cancer from returning or growing further. During the course of the study, the presence of cancer in the blood will be monitored regularly to track how the body responds to the medication.

The purpose of this study is to find the best amount and timing of indocyanine green to create enough difference in brightness between the tumor and normal tissue, and to check whether this glowing effect can help surgeons accurately identify the edges of tumors during surgery. The study will look at how well the fluorescence imaging, which is a technique that uses special cameras to see the glowing substance, matches with what is found when tissue is examined under a microscope after removal. Researchers will also count how many additional glowing areas are found and confirmed to be cancer, as well as cases where the glow incorrectly suggests cancer when there is none or misses cancer that is present.

During the study, patients who are already planned to have surgery to remove their cancer will receive an infusion of indocyanine green before or during their operation. Surgeons will use special cameras that can detect the fluorescence to look at the tumor area and the surrounding tissue. The removed tissue and any lymph nodes will be examined both with the fluorescence camera and later under a microscope to compare the results. The study will measure the brightness difference between tumor and normal tissue, check whether the edges of the removed tissue are free of cancer cells, and record any side effects that occur. The goal is to determine if this imaging method can help surgeons remove cancer more completely while preserving healthy tissue.

The purpose of this study is to investigate the cardiovascular side effects of immune checkpoint inhibitors, which means looking at how these cancer treatments might affect the heart and blood vessels. The study will monitor patients who are receiving these treatments as part of their regular cancer care. During the study, doctors will check for various heart-related problems that might develop or get worse during treatment. The treatment period with these medicines can last up to twelve months.

The main focus of the study is to track serious heart-related events, including death from heart problems, heart attacks, strokes, chest pain that requires hospital care or urgent treatment to restore blood flow to the heart, and hospital stays due to heart failure (when the heart cannot pump blood well enough). The study will also look at other heart and blood vessel problems such as new or worsening high blood pressure, irregular heartbeats, blood clots in the veins, and other heart-related issues that require hospital admission. This research aims to better understand how these cancer treatments affect the heart and blood vessels so that doctors can better monitor and care for patients receiving these medicines.

The main purpose of this research is to examine how CBD affects muscle health and energy production in muscle cells (mitochondrial activity) in people with head and neck cancer. Participants will take either Arvisol tablets or placebo tablets along with nutritional supplements for up to 21 days. The maximum daily dose of the medication will be 450 mg.

During the study, researchers will monitor various aspects of muscle health using different measurement techniques. They will assess muscle strength, muscle mass, and overall physical performance. The study will also track how well participants tolerate the treatment by monitoring their appetite and any digestive issues they may experience. Additionally, the research team will evaluate how the cancer responds to treatment using medical imaging.

The main purpose of this study is to determine how effective a short course of mitazalimab treatment is for people with high-risk mouth disorders. During the study, participants will receive the medication through solution for infusion directly into the affected areas of their mouth. The total treatment period will last up to 8 weeks, with specific doses calculated based on body weight.

The study will monitor changes in the mouth conditions over time, particularly focusing on improvements after 6 months of treatment. Participants will need to provide mouth tissue samples and saliva samples throughout the study period. The overall monitoring of participants will continue for several years to track long-term outcomes and any changes in the mouth conditions.

Participants in the study will receive either the NBTXR3 treatment activated by radiotherapy, with or without cetuximab, or they will receive radiotherapy with or without cetuximab alone. Radiotherapy is a treatment that uses high doses of radiation to kill cancer cells and shrink tumors. The study will compare the outcomes of these different treatment options to see which is more effective in preventing the cancer from coming back or spreading.

The study will follow participants over a period of time to monitor their health and the progression of their cancer. The main goal is to see how long patients live without the cancer getting worse, which is known as progression-free survival. This information will help doctors understand the best treatment options for patients with this type of cancer who are not able to undergo standard chemotherapy treatments.

The purpose of the study is to assess the short-term effects of these cancer treatments on speech perception in noise. Participants will undergo various assessments to measure changes in their ability to understand speech in noisy settings, as well as changes in their hearing and cognitive functions. The study will also evaluate the impact of these treatments on the participants’ quality of life related to hearing. The trial will follow participants from the start of their treatment and include follow-up visits to monitor any changes over time.

By participating in this study, researchers aim to gain a better understanding of how cancer treatments affect important aspects of daily life, such as communication and cognitive abilities. This information could help improve future treatment plans and support services for individuals undergoing cancer therapy. The study is expected to continue until the end of 2031, with recruitment starting in August 2024.

The purpose of the study is to validate the effectiveness of this hybrid tracer in accurately identifying sentinel nodes. The study will compare the results of using the hybrid tracer with the standard method, which uses only Technetium (99mTc) Nanocolloid. Participants will receive an injection of the tracer substances, and imaging techniques such as lymphoscintigraphy and SPECT/CT will be used to visualize the sentinel nodes before surgery. The study aims to ensure that the hybrid tracer can reliably identify the same number of sentinel nodes as the standard method.

Throughout the study, researchers will monitor the number and intensity of the nodes detected by both the hybrid tracer and the standard method. This will help determine if the new method is as effective as the current standard in identifying sentinel nodes. The study is expected to provide valuable information that could improve the accuracy of sentinel node biopsies in patients with these types of cancer.

The purpose of this study is to evaluate how well the combination of these two drugs works in terms of reducing the size of the tumor. Participants in the study will receive both medications over a period of up to 12 months. The study is designed to observe the response of the cancer to this treatment combination, which targets specific proteins involved in cancer growth.

This trial is open-label, meaning that both the researchers and participants will know which treatments are being administered. The study is being conducted at multiple centers, allowing for a broader range of participants. The goal is to gather information on the effectiveness of this treatment combination in managing head and neck cancer that has not responded to previous therapies.

The purpose of the study is to evaluate how well CEUS can identify sentinel nodes during surgery compared to the current standard method. Participants will undergo a procedure where the Sonazoid contrast agent is injected, and the sentinel nodes are then located using the CEUS technique with the help of a device called the BK5000 US device. This study aims to determine the accuracy of CEUS in finding these nodes and to see if it can predict whether the nodes are cancerous.

Throughout the study, researchers will monitor the time it takes to locate the sentinel nodes using CEUS and assess the ease of using the CEUS system. The study will provide valuable information on whether this method can be a reliable alternative to existing techniques for detecting sentinel nodes in patients with these types of cancer.

The trial will include patients with various types of advanced cancers, such as non-small cell lung cancer, renal cell carcinoma, urothelial bladder cancer, head and neck squamous cell cancer, breast cancer, gastric or gastroesophageal adenocarcinoma, epithelial ovarian cancer, cervical cancer, endometrial adenocarcinoma, prostate cancer, and soft tissue sarcoma. The study will be conducted in two phases. The first phase will focus on finding the right dose of JK06 by gradually increasing the amount given to patients. The second phase will involve giving the selected dose to more patients to further evaluate its effects.

Throughout the study, patients will receive the treatment every three weeks and will be monitored closely for any side effects or changes in their condition. The goal is to gather information that will help in developing JK06 as a potential treatment option for people with these types of advanced cancers. The study is expected to continue until 2028, with recruitment starting in 2024.

The study will investigate how hydroxychloroquine affects both the cancer cells and the immune system cells around the tumor. Patients will receive the medication before their planned surgery. The medication will be taken by mouth, with a maximum daily dose of 1200 mg and can be given for up to 15 days.

After the surgery, researchers will examine the removed tumor tissue to understand how the medication affected the cancer cells and the surrounding tissue. They will look for specific markers that show changes in the tumor cells and immune system responses. This will help determine if hydroxychloroquine could be beneficial as part of cancer treatment.

The purpose of this study is to compare the effects of continuing standard immunotherapy with a reduced dose of the same treatment. The medications being studied include Pembrolizumab, Durvalumab, Avelumab, Nivolumab, Dostarlimab, Atezolizumab, and Cemiplimab. These medications are given through an intravenous infusion, which means they are administered directly into the bloodstream through a vein. Some patients will receive the standard dose of these medications, while others will receive a reduced dose every three months.

The study will last for up to three years, during which time patients will continue to receive their assigned treatment. The main goal is to see if the reduced dose is as effective as the standard dose in keeping the cancer from getting worse. Patients will have regular check-ups and assessments to monitor their health and the progress of their cancer. The study will also look at other factors, such as the quality of life and any side effects experienced by the patients. This research aims to find the best way to use immunotherapy to treat cancer effectively while minimizing side effects.

The purpose of the study is to compare the effectiveness of the capsaicin patch with the amitriptyline solution in reducing pain in the cervico-facial area, which is the neck and face region. Participants will receive either the capsaicin patch or the amitriptyline solution over a period of nine months. The capsaicin patch will be applied every three months, while the amitriptyline solution will be taken orally. Some participants may receive a placebo, which is a treatment with no active medication, to help researchers understand the true effects of the treatments being tested.

Throughout the study, participants will be monitored to see if their pain decreases by at least two points on a pain scale over the nine-month period. The study will also assess any side effects from the treatments and how the treatments impact the participants’ quality of life. This information will help determine which treatment is more effective for managing neuropathic pain in patients who have had head and neck cancer.

The purpose of the study is to evaluate the safety and effectiveness of Tolinapant in treating these advanced cancers. Participants in the study will receive the medication in the form of a capsule taken by mouth. The study will be conducted in phases, with the first phase already completed. The second phase will focus on assessing how well the medication works in reducing the size of tumors or slowing their growth. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of Tolinapant.

Throughout the study, participants will be monitored for any side effects and changes in their condition. The study aims to determine the best dose of Tolinapant and to gather information on how the body processes the medication. This information will help researchers understand the potential benefits and risks of using Tolinapant as a treatment for advanced cancers. The study is expected to continue until the end of 2025.

The purpose of the study is to see if these medications can help prevent the cancer from coming back after surgery. The study will have two groups of patients. One group will receive nivolumab alone, and the other group will receive a combination of nivolumab and ipilimumab. The study will last for about two years, during which time the patients will be monitored to see if the cancer returns and to check for any side effects from the medications.

Participants in the study will receive treatment for up to six months, and their health will be checked regularly. The study aims to find out if these treatments can help patients live longer without the cancer coming back. This research is important because it could lead to better treatment options for people with high-risk recurrent head and neck cancer.

The trial will compare the effectiveness of using NBTXR3 with radiation therapy alone or in combination with a medication called Cetuximab. Cetuximab is a type of protein used to treat certain cancers by blocking the growth of cancer cells. The study aims to see if this combination can improve survival outcomes for patients who cannot receive a standard chemotherapy treatment known as platinum-based chemotherapy. This is particularly relevant for elderly patients who may not tolerate standard treatments well.

Participants in the study will receive either the new treatment combination or the standard treatment, which may include radiation therapy with or without Cetuximab. The study will monitor the participants over time to assess how well the treatments work in controlling the cancer and improving survival. The goal is to find out if the new treatment approach can offer better results for patients with this type of cancer.

The purpose of the study is to see if this new method can help identify the primary tumor in the upper part of the throat and digestive tract. Participants will undergo a procedure where the fluorescent tracer is given through an intravenous infusion, meaning it is delivered directly into the bloodstream. After the tracer is administered, doctors will use a special camera to look for the glowing areas that might indicate the presence of cancer. This process is expected to help in locating the primary tumor that was not found during standard tests like physical exams, X-rays, or CT scans.

The study will observe how well the tracer works in highlighting cancerous areas and will compare these findings with traditional methods. It will also collect information about the participants, such as their age, sex, and medical history, to understand how these factors might affect the results. The study will also assess the quality of life of participants before and after the procedure to ensure their well-being. The trial is expected to continue until the end of 2026, with the aim of improving the detection of primary tumors in patients with this challenging condition.

The purpose of the study is to assess the safety and tolerability of these treatments, which means checking for any side effects and determining how well patients can handle the medications. The study will also gather preliminary information on how effective these treatments are in managing the disease. Participants will receive the medications in different doses and combinations to find the most effective and safest way to use them. The trial will also explore if a more convenient dosing schedule can be established for patients.

Throughout the study, participants will be monitored for any adverse events, which are unwanted effects that may occur during treatment. The trial will also measure how the body processes the medications, including how long they stay in the body and how they are eliminated. The study will continue until the estimated end date in 2026, with the goal of providing valuable information on the potential benefits of Relatlimab and Nivolumab for treating advanced solid tumors.

The study is divided into two phases. In the first phase, participants will receive different doses of IPN01194 to determine the safest and most effective dose. This phase will also monitor any side effects that may occur. In the second phase, the study will focus on how well the treatment works in reducing the size of the tumors. Participants will be closely monitored throughout the study to assess their response to the treatment and any changes in their condition.

Participants in the study will receive either the medication IPN01194 or a placebo. The study aims to gather information on how the body processes the medication and its impact on the tumors. This information will help researchers understand the potential benefits and risks of IPN01194 for treating these types of cancers. The study is expected to continue for several years to ensure comprehensive data collection and analysis.

The purpose of this study is to see how well the combination of ALX148 and pembrolizumab works in improving the survival rate and response to treatment in patients with this type of cancer. Participants in the study will receive these treatments over a period of up to 24 months. The study will monitor how the cancer responds to the treatment and how long the effects last. It will also look at the safety of the treatment and any side effects that may occur.

Throughout the study, participants will have regular visits to the clinic for treatment and check-ups. These visits will include various tests to monitor the cancer and overall health. The study aims to provide valuable information on the effectiveness of combining ALX148 with pembrolizumab for treating advanced head and neck squamous cell carcinoma.

The purpose of this study is to understand the safety and tolerability of JK08, as well as to determine the best dose for patients. The study will begin with a phase where different doses of JK08 are tested to find the maximum dose that patients can tolerate. After this, the study will expand to include more patients to further evaluate the optimal dose. Patients participating in the study will receive JK08 through subcutaneous use, which means it is injected under the skin. Some patients may also receive Keytruda through infusion, which is a method of delivering medication directly into the bloodstream, or Lenvima in the form of hard capsules taken orally.

This trial is open to patients with various types of advanced cancers, including non-small cell lung cancer, small cell lung cancer, melanoma, renal cell carcinoma, urothelial cancer, head and neck squamous cell cancer, breast cancer, gastric cancer, esophageal cancer, pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, endometrial cancer, and thyroid cancer. The study aims to provide new insights into the treatment of these cancers and potentially offer new therapeutic options for patients who have limited treatment choices.

The purpose of the study is to evaluate how effective this combination of treatments is in improving the survival rate and response to treatment in patients who have not yet received treatment for their advanced cancer. Participants in the study will receive these treatments through an intravenous (IV) line, which means the medication is given directly into a vein. The study will last for up to 24 months, during which time the effects of the treatment will be closely monitored.

Throughout the study, researchers will assess various outcomes, such as how long patients live after starting the treatment and how well the cancer responds to the treatment. They will also monitor any side effects that may occur. This information will help determine if the combination of ALX148, pembrolizumab, and chemotherapy is a beneficial treatment option for patients with advanced head and neck squamous cell carcinoma.

The purpose of the study is to evaluate how well Disitamab Vedotin works in treating these cancers. Participants in the study will receive the treatment as a powder mixed into a solution, which is then given through an infusion. The study will follow participants over a period of time to observe the effects of the treatment on their cancer. Some participants may receive a placebo, which is a substance with no active medication, to compare the results.

Throughout the study, researchers will monitor the participants’ health and any changes in their cancer. They will look at how the cancer responds to the treatment, any side effects that occur, and how long the effects last. The study aims to provide valuable information on the effectiveness and safety of Disitamab Vedotin for these types of cancer.

The purpose of the study is to compare the effects of the combination of Monalizumab and Cetuximab with the combination of placebo and Cetuximab. The study will look at how long patients live after starting the treatment. Participants will be randomly assigned to one of the two groups: one group will receive Monalizumab and Cetuximab, and the other group will receive a placebo and Cetuximab. The study will be conducted in a way that neither the participants nor the researchers know who is receiving Monalizumab or the placebo, which is known as a double-blind study.

Throughout the study, participants will receive their assigned treatments through an infusion, which means the medicine is given directly into a vein. The study will also involve regular check-ups and tests to monitor the participants’ health and the effects of the treatment. These tests may include blood tests and other assessments to check for any side effects and to measure the concentration of Monalizumab in the blood. The study aims to provide valuable information on whether the new treatment combination can improve survival for patients with this type of cancer.

The purpose of the study is to evaluate how safe and effective these treatments are when used together in patients with advanced stages of these HPV-16 related cancers. The study will be conducted in two phases. In the first phase, the focus will be on understanding the safety and how well patients tolerate the combination of avelumab and TG4001. In the second phase, the study will look at how well the combination works in terms of slowing down the progression of the cancer compared to using avelumab alone.

Participants in the study will receive the treatments through injections or infusions, and their health will be monitored over time to see how the cancer responds to the treatment. The study aims to provide valuable information on whether this combination of treatments can offer a new option for patients with these types of cancers.

The purpose of the study is to see how well this imaging method can detect tiny amounts of cancer that might remain after surgery. During the trial, participants will undergo surgery to remove the cancer, and the imaging technique will be used to check the surgical area for any remaining cancer cells. This will help doctors ensure that as much of the cancer as possible is removed during the operation.

Participants in the study may receive either the imaging technique with indocyanine green or a placebo. The study will monitor the effectiveness of the imaging method in identifying cancer cells and will also track any side effects experienced by participants. The goal is to improve surgical outcomes for patients with epidermoid carcinoma by providing surgeons with better tools to ensure all cancerous tissue is removed.

The purpose of the study is to compare the effectiveness of the combination of xevinapant and cetuximab with radiotherapy against the standard treatment of cetuximab with radiotherapy and a placebo. Participants in the study will be randomly assigned to receive either the new treatment combination or the standard treatment. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the new treatment or the standard treatment until the study is completed. This helps ensure that the results are not biased.

Throughout the study, participants will receive regular assessments to monitor their health and the progress of their cancer. The study aims to determine if the new treatment combination can improve outcomes for patients who are not suitable for high-dose chemotherapy. The trial will last for several years, allowing researchers to gather enough data to make informed conclusions about the treatment’s effectiveness and safety.

Participants in the study will be randomly assigned to receive either the new treatment with LSTA1 or a placebo, along with their standard care. The study will be conducted over a period of up to 52 weeks, during which participants will receive their assigned treatments through intravenous infusions. The study will monitor the incidence and severity of any side effects, as well as other outcomes such as overall survival, progression-free survival, and response to the treatment.

The goal of this research is to determine if the addition of LSTA1 can improve the outcomes for patients with these types of cancers. By participating in this study, researchers hope to gather valuable information that could lead to better treatment options in the future. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the new treatment or the placebo, to ensure unbiased results.

The study is divided into two parts. In the first part, participants will receive DS-3939a to assess its safety and how well it is tolerated by the body. In the second part, the study will continue to evaluate safety and also measure the treatment’s effectiveness at a recommended dose. This will involve looking at how the cancer responds to the treatment, which is known as the objective response rate. Participants may have different types of advanced cancers, including those of the lung, breast, ovary, and pancreas, among others.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. This includes regular check-ups, laboratory tests, and imaging studies to track the progress of the treatment. The study aims to gather important information that could lead to new treatment options for people with advanced solid tumors. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of DS-3939a.